Sonnet BioTherapeutics Holdings, Inc. Logo

Sonnet BioTherapeutics Holdings, Inc.

Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.

SONN | US

Overview

Corporate Details

ISIN(s):
US83548R1059
LEI:
Country:
United States of America
Address:
100 OVERLOOK CENTER, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic medicines. The company's core technology is its proprietary Fully Human Albumin-Binding (FHAB™) platform, which utilizes a single-chain antibody fragment (scFv) that binds to the body's own albumin. This 'hitch-hiking' mechanism is designed to deliver cytokine payloads directly to tumor tissues, enhancing drug penetration, retention, and local activation. Sonnet's therapeutic goal is to convert immunologically 'cold' tumors into 'hot' tumors, thereby making them more responsive to treatment. The company's pipeline consists of several cytokine-derived therapeutic candidates in clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sonnet BioTherapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonnet BioTherapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sonnet BioTherapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia
SKF

Talk to a Data Expert

Have a question? We'll get back to you promptly.